Developing Non-Opioid Pain Medication with Reduced Abuse Potential with Ketan Mehta Tris Pharma

Ketan Mehta, Founder and CEO of Tris Pharma, is focused on developing non-addictive pain medication. Their lead drug candidate is designed to be an effective pain drug without the respiratory-depressive and addictive side effects of traditional opioid drugs. This drug works by targeting the nociceptin receptor and has also shown promise to help curb cravings and dependence on opioids. The goal is to provide doctors and patients with a non-opioid pain medication option that can help reduce reliance on highly addictive prescription opioids.  Ketan explains, "Tris is focused on neuroscience-based products, especially CNS, at a high level. More specifically, we focused on ADHD and neurodevelopmental disorders and the products that treat them. And also, more recently, we have been more active in the pain space." "We're developing a drug, which is currently an investigational drug in Phase three clinical trials. It's called cebranopadol. And what we have seen is that it has an efficacy just on par with your typical traditional opioid. It's highly effective from what we have seen in more than 2,000 patients to date. But also, what we're seeing thus far is that there is no indication that it creates dependency. You can just taper off the patients, meaning you don't have to give lesser dose even after pain has subsided. And it does not give you the level of respiratory depression or failure that we see with the traditional opioid." "Right now, we're conducting our first trials in acute pain, and then we will look at any kind of moderate to severe pain. Essentially like chronic pain, lower back pain, for example, the pain in arthritis, cancer pain, other disease conditions like fibromyalgia, or just any kind of injury that gives you pretty much any nociceptive pain that one would encounter, we expect, like diabetic peripheral neuropathy and so forth." #TrisPharma #PainManagement #ClinicalTrial #Innovation #PainTherapy #Cebranopadol  trispharma.com Download the transcript here